The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
Global rights (excluding North America) to ThermaCare (United Kingdom)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
Faes Farma, flagship product Bilastine
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Alteon Health
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
Morgans Hotel Group
Advised the Special Transaction Committee of the Board of Morgans Hotel Group on the transfer of its ownership interests in Delano South Beach and The Light Group to The Yucaipa Companies in exchange for the cancellation of certain securities held by Yucaipa (debt, preferred stock and warrants) together with a $100 million rights offering backstopped by Yucaipa
Cerner RevWorks
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
Forest City Ratner
Advised Forest City Enterprises, Inc. on the restructuring of its business relationship with its New York City affiliate Forest City Ratner
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
MGM Hakkasan Hospitality
Advised MGM Resorts International on the formation of a joint venture hotel management company with the Hakkasan Group called MGM Hakkasan Hospitality that will design, develop and manage luxury non-gaming hotels worldwide
Allied Healthcare
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
Boehringer Ingelheim
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
Total Care Medicaid Plan
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
Surgery Partners’ Anesthesia Services
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Aisthesis
Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
US Acute Care Solutions
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Fidelis SeniorCare Inc. (Michigan Heath Plan)
Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
Pfizer Inc. Consumer Health Business
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture